AnaptysBio, Inc. $ANAB shares tumbled 71% to $10.61 after the company reported that its Etokimab ATLAS Phase 2b trial in moderate-to-sever Atopic Dermatitis failed to meet its primary endpoint. The company also reported Q3 EPS down from last year.